Cited by 91Atrial Fibrillation Management and OutcomesCardiac Arrhythmias and TreatmentsCardiac pacing and defibrillation studies

Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy

Gaita, Fiorenzo, Di Donna, Paolo, Olivotto, Iacopo, Scaglione, Marco, Ferrero, Ivana, Montefusco, Antonio, Caponi, Domenico, Conte, Maria Rosa +2 more·2007·The American Journal of Cardiology

Abstract

Atrial fibrillation (AF) is common in patients with hypertrophic cardiomyopathy (HC) and predicts adverse outcome. Radiofrequency catheter ablation (RFCA) represents a potentially advantageous alternative to lifelong pharmacologic treatment. However, its efficacy in patients with HC is not established. In the present study, the feasibility, safety, and efficacy of RFCA of AF in patients with HC were evaluated. Twenty-six patients with HC with paroxysmal (n = 13) or permanent (n = 13) AF refractory to antiarrhythmic therapy (age 58 +/- 11 years, time from AF onset 7.3 +/- 6.2 years, left atrial volume 170 +/- 48 ml) underwent RFCA. A schema with pulmonary vein isolation plus linear lesions was used. No major periprocedural complication occurred. One patient died from a hemorrhagic stroke 4 weeks after RFCA while in sinus rhythm. During a 19 +/- 10-month follow-up, 9 of the remaining 25 patients (36%) experienced recurrence of AF (despite repeated RFCA in 3) and were considered failures, whereas 16 remained in sinus rhythm (i.e., 64% overall success rate). Ten of these 16 patients were off antiarrhythmic drug therapy at final evaluation. RFCA was highly successful in patients with paroxysmal AF (77% success rate compared with 50% in the subgroup with permanent AF). Patients with restoration of sinus rhythm showed marked symptomatic improvement (final New York Heart Association functional class 1.2 +/- 0.5 vs 1.7 +/- 0.7 before the procedure, p = 0.003). Conversely, patients for whom RFCA failed showed no change (final functional class 1.9 +/- 0.8 vs 1.7 +/- 0.9 before the procedure, p = 0.59). In conclusion, in most studied patients with HC, RFCA proved a safe and effective therapeutic option for AF, improved functional status, and was able to reduce or postpone the need for long-term pharmacologic treatment.

Integrity signals

Registry

Crossref · 10.1016/j.amjcard.2006.12.087

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Gaita, F., Di Donna, P., Olivotto, I., Scaglione, M., Ferrero, I., Montefusco, A., Caponi, D., Conte, M. R., Nistri, S., & Cecchi, F.
Affiliations
  • Azienda Ospedaliero-Universitaria Careggi (IT)
  • Azienda Sanitaria Locale di Asti (IT)
  • Ospedale degli Infermi (IT)
Venue
The American Journal of Cardiology
Publisher
Elsevier BV
Published
2007-06
Volume
99
Issue
11
Pages
1575-1581
ISSN
0002-9149 (ISSN-L)
OpenAlex
W2166808786
Cited by
91
References
27
Citations by year
2026: 1 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 2 · 2021: 3 · 2020: 3 · 2019: 2 · 2018: 5 · 2017: 6 · 2016: 7 · 2015: 7 · 2014: 11 · 2013: 8 · 2012: 5
FWCI
3.51
Type
journal article
Language
en
Open access
closed
Locations
  • The American Journal of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
  • Florence Research (University of Florence) (submittedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac pacing and defibrillation studies
Keywords
atrial fibrillation, hypertrophic cardiomyopathy, radiofrequency catheter ablation, pulmonary vein isolation, paroxysmal atrial fibrillation, permanent atrial fibrillation, antiarrhythmic drug withdrawal, sinus rhythm restoration, procedural safety, arrhythmia recurrence, NYHA functional class
MeSH terms
Adult, Aged, Aged, 80 and over, Anti-Arrhythmia Agents, Atrial Fibrillation, Cardiomyopathy, Hypertrophic, Equipment Safety, Feasibility Studies, Female, Follow-Up Studies, Heart Conduction System, Humans, Italy, Male, Middle Aged, Predictive Value of Tests, Echocardiography, Doppler, Electrocardiography, Ambulatory, Survival Analysis, Atrial Function, Treatment Outcome, Catheter Ablation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review